In breast cancer, the incidence of pneumonia in combination therapy for breast cancer ranges from 1-7%, which is higher in patients receiving anti-PD-1 therapy compared with anti-PD-L1 therapy alone or in combination (Figure 3C) (Figure 4C). This evidence concerns the gene CD274 and susceptibility to pneumonia measurement.